Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Dow
Johnson and Johnson
Harvard Business School
Baxter

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

KLONOPIN RAPIDLY DISINTEGRATING Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Klonopin Rapidly Disintegrating patents expire, and what generic alternatives are available?

Klonopin Rapidly Disintegrating is a drug marketed by Roche and is included in one NDA.

The generic ingredient in KLONOPIN RAPIDLY DISINTEGRATING is clonazepam. There are ten drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the clonazepam profile page.

Drug patent expirations by year for KLONOPIN RAPIDLY DISINTEGRATING
Recent Litigation for KLONOPIN RAPIDLY DISINTEGRATING

Identify potential future generic entrants

District Court Litigation
Case NameDate
Forest Laboratories LLC v. Sigmapharm Laboratories LLC2014-09-03
SCHERING CORPORATION v. SANDOZ INC.2008-04-03
Plaintiff(s) v. Defendant(s)2008-01-31

See all KLONOPIN RAPIDLY DISINTEGRATING litigation

Synonyms for KLONOPIN RAPIDLY DISINTEGRATING
1,3-Dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one
1,4.benzodiazepin-2-one
106955-87-7
1622-61-3
2-H-1, 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-
2-H-1,4-Benzodiazepin-2-one, 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-
2H-1, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-
2H-1, 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-
2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-
2H-1,4-Benzodiazepin-2-one, 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-
5-(2-Chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-one
5-(2-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one
5-(2-Chlorophenyl)-1,4-benzodiazepin-2-one
5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one
5-(2-Chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one
5-(2-Chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one #
5-(2-chlorophenyl)-7-nitro-1H-benzo[e][1,4]diazepin-2(3H)-one
5-(2-chlorophenyl)-7-nitro-2,3-dihydro-1H-1,4-benzodiazepin-2-one
5-(2-Chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2(1H)-one
5-(o-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one
5-(o-Chlorophenyl)-1,4-benzodiazepin-2-one
5-(o-chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one
5-(o-Chlorophenyl)-7-nitro-1H-1,4-benzodiazepin-2(3H)-one
5-24-04-00351 (Beilstein Handbook Reference)
5PE9FDE8GB
622C613
7-nitro-1,3-dihydro-5-(o-chlorophenyl)-2H-1,4-benzodiazepin-2-one
7-Nitro-5-(2-chlorophenyl)-3H-1,4-benzodiazepin-2(1H)-one
A810362
AB01563349_01
AC-15733
AC1L1EI2
AKOS015902192
Alti-Clonazepam
AN-49558
Antelepsin
Antilepsin
Apetryl
BAS 00308658
BC209470
BDBM50019213
BIDD:PXR0144
BRN 0759557
C-19452
C15H10ClN3O3
CC-25924
CCG-213669
CHEBI:3756
CHEMBL452
Chlonazepam
Cloazepam
clonazepam
Clonazepam (JP17/USP/INN)
Clonazepam [USAN:INN:BAN:JAN]
Clonazepam [USAN:USP:INN:BAN:JAN]
Clonazepam 0.1 mg/ml in Methanol
Clonazepam 1.0 mg/ml in Methanol
Clonazepam fine granules (JP17)
Clonazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
Clonazepam solution, drug standard, 1.0 mg/mL in methanol
Clonazepam tablets (JP17)
clonazepam--dea schedule iv item
Clonazepam, European Pharmacopoeia (EP) Reference Standard
Clonazepam, powder
Clonazepamum
Clonazepamum [INN-Latin]
Clonex
Clonopin
CTK4A4881
D00280
DB01068
DEA No. 2737
DGBIGWXXNGSACT-UHFFFAOYSA-N
DivK1c_000973
DTXSID1022845
EINECS 216-596-2
FT-0603203
GTPL6963
HMS2093H22
HMS503C07
HSDB 3265
I14-1364
IDI1_000973
Iktorivil
Jsp003251
KBio1_000973
Kenoket
Klonopin
Klonopin (TN)
Landsen
Lktorivil
Lonazep
LS-34156
LS-34260
Melzap
MLS003899214
NINDS_000973
NSC 179913
NSC-179913
NSC179913
Oprea1_168772
Paxam
Ravotril
Rivatril
Rivoril
Rivotril
Ro 4-8180
Ro 4023
Ro 5-4023
Ro 5-4023/B-7
Ro 54023
Ro-5-4023
Ro-54023
RO4023
SBI-0206863.P001
SCHEMBL38899
SMR000058982
Solfidin
SR-01000937610
SR-01000937610-2
UNII-5PE9FDE8GB
WLN: T67 GMV JN IHJ CNW KR BG
ZINC3813003

US Patents and Regulatory Information for KLONOPIN RAPIDLY DISINTEGRATING

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Roche KLONOPIN RAPIDLY DISINTEGRATING clonazepam TABLET, ORALLY DISINTEGRATING;ORAL 020813-001 Dec 23, 1997 DISCN Yes No   Start Trial   Start Trial   Start Trial
Roche KLONOPIN RAPIDLY DISINTEGRATING clonazepam TABLET, ORALLY DISINTEGRATING;ORAL 020813-004 Dec 23, 1997 DISCN Yes No   Start Trial   Start Trial   Start Trial
Roche KLONOPIN RAPIDLY DISINTEGRATING clonazepam TABLET, ORALLY DISINTEGRATING;ORAL 020813-002 Dec 23, 1997 DISCN Yes No   Start Trial   Start Trial   Start Trial
Roche KLONOPIN RAPIDLY DISINTEGRATING clonazepam TABLET, ORALLY DISINTEGRATING;ORAL 020813-003 Dec 23, 1997 DISCN Yes No   Start Trial   Start Trial   Start Trial
Roche KLONOPIN RAPIDLY DISINTEGRATING clonazepam TABLET, ORALLY DISINTEGRATING;ORAL 020813-005 Dec 23, 1997 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for KLONOPIN RAPIDLY DISINTEGRATING

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Roche KLONOPIN RAPIDLY DISINTEGRATING clonazepam TABLET, ORALLY DISINTEGRATING;ORAL 020813-005 Dec 23, 1997   Start Trial   Start Trial
Roche KLONOPIN RAPIDLY DISINTEGRATING clonazepam TABLET, ORALLY DISINTEGRATING;ORAL 020813-004 Dec 23, 1997   Start Trial   Start Trial
Roche KLONOPIN RAPIDLY DISINTEGRATING clonazepam TABLET, ORALLY DISINTEGRATING;ORAL 020813-001 Dec 23, 1997   Start Trial   Start Trial
Roche KLONOPIN RAPIDLY DISINTEGRATING clonazepam TABLET, ORALLY DISINTEGRATING;ORAL 020813-002 Dec 23, 1997   Start Trial   Start Trial
Roche KLONOPIN RAPIDLY DISINTEGRATING clonazepam TABLET, ORALLY DISINTEGRATING;ORAL 020813-002 Dec 23, 1997   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Baxter
Medtronic
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.